News >

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

Audrey Sternberg
Published: Thursday, Nov 07, 2019

Leslie M. Randall, MD, MAS

Leslie M. Randall, MD, MAS
As PARP inhibitors (PARPi) have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication